欧州連合 - ラトビア語 - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklīdu attēlveidošana - terapeitiskie radiofarmaceitiskie preparāti - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

欧州連合 - ラトビア語 - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

欧州連合 - ラトビア語 - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

ラトビア - ラトビア語 - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotās tabletes - 160 mg/25 mg

ラトビア - ラトビア語 - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotās tabletes - 80 mg/12,5 mg

ラトビア - ラトビア語 - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotās tabletes - 160 mg/12,5 mg

ラトビア - ラトビア語 - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotās tabletes - 320 mg/12,5 mg

ラトビア - ラトビア語 - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - valsartanum, hydrochlorothiazidum - apvalkotās tabletes - 320 mg/25 mg

ラトビア - ラトビア語 - Zāļu valsts aģentūra

divapharma gmbh, germany - ambroksola hidrohlorīds - sūkājamā tablete - 15 mg

ラトビア - ラトビア語 - Zāļu valsts aģentūra

sopharma ad, bulgaria - thiamini hydrochloridum, riboflavinum, pyridoxini hydrochloridum, nicotinamidum - Šķīdums injekcijām